Pasar al contenido principal

INGENIERIA DE MYCOPLASMA PNEUMONIAE PARA EL TRATAMIENTO DE CANCER DE PULMON

PID2021-122341NB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO CENTRE DE REGULACIO GENOMICA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Engineering Mycoplasma pneumoniae to bypass the association with Guillain-Barré syndrome

  • Broto, Alicia|||0000-0002-3275-8524
  • Piñero-Lambea, Carlos|||0000-0002-5263-3702
  • Segura-Morales, Carolina|||0000-0002-1746-6865
  • Tio-Gillen, Anne P.
  • Unger, Wendy W.J.
  • Burgos Castellanos, Raül|||0000-0002-4452-9235
  • Mazzolini, Rocco|||0000-0003-3249-8387
  • Miravet-Verde, Samuel
  • Jacobs, Bart C.|||0000-0002-8985-2458
  • Casas, Josefina|||0000-0002-7926-5209
  • Huizinga, Ruth
  • Lluch-Senar, Maria|||0000-0001-7568-4353
  • Serrano, Luis|||0000-0002-5276-1392
A non-pathogenic Mycoplasma pneumoniae -based chassis is leading the development of live biotherapeutic products (LBPs) for respiratory diseases. However, reports connecting Guillain-Barré syndrome (GBS) cases to prior M. pneumoniae infections represent a concern for exploiting such a chassis. Galactolipids, especially galactocerebroside (GalCer), are considered the most likely M. pneumoniae antigens triggering autoimmune responses associated with GBS development. In this work, we generated different strains lacking genes involved in galactolipids biosynthesis. Glycolipid profiling of the strains demonstrated that some mutants show a complete lack of galactolipids. Cross-reactivity assays with sera from GBS patients with prior M. pneumoniae infection showed that certain engineered strains exhibit reduced antibody recognition. However, correlation analyses of these results with the glycolipid profile of the engineered strains suggest that other factors different from GalCer contribute to sera recognition, including total ceramide levels, dihexosylceramide (DHCer), and diglycosyldiacylglycerol (DGDAG). Finally, we discuss the best candidate strains as potential GBS-free Mycoplasma chassis.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Heterologous protein exposure and secretion optimization in Mycoplasma pneumoniae

  • Ana, Yamile
  • Gerngross, Daniel
  • Serrano Pubull, Luis, 1982-
The non-pathogenic Mycoplasma pneumoniae engineered chassis (Mycochassis) has demonstrated the ability to express therapeutic molecules in vitro and to be effective for treatment of lung infectious diseases in in vivo mouse models. However, the expression of heterologous molecules, whether secreted or exposed on the bacterial membrane has not been optimized to ensure sufficient secretion and/or exposure levels to exert a maximum in vivo biological effect. Here, we have improved the currently used secretion signal from MPN142 protein. We found that mutations at P1' position of the signal peptide cleavage site do not abrogate secretion but affect it. Increasing hydrophobicity and mutations at the C-terminal of the signal peptide increases secretion. We tested different lipoprotein signal peptides as possible N-terminal protein anchoring motifs on the Mpn cell surface. Unexpectedly we found that these peptides exhibit variable retention and secretion rates of the protein, with some sequences behaving as full secretion motifs. This raises the question of the biological role of the lipobox motif traditionally thought to anchor membrane proteins without a helical transmembrane domain. These results altogether represent a step forward in chassis optimization, offering different sequences for secretion or membrane retention, which could be used to improve Mycochassis as a delivery vector, and broadening its therapeutic possibilities., This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreements No 670216 and 101020135). We also acknowledge the support of the Spanish Ministry of Science, Innovation and Universities through the Plan Nacional PID2021-122341NB-I00 funded by MICIU/AEI/10.13039/501100011033/FEDER, UE.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Using single-cell perturbation screens to decode the regulatory architecture of splicing factor programs

  • Anglada-Girotto, Miquel
  • Miravet Verde, Samuel, 1992-
  • Serrano Pubull, Luis, 1982-
Splicing factors shape the isoform pool of most transcribed genes, playing a critical role in cellular physiology. Their dysregulation is a hallmark of diseases like cancer, where aberrant splicing contributes to progression. While exon inclusion signatures accurately assess changes in splicing factor activity, systematically mapping disease-driver regulatory interactions at large scale remains challenging. Perturb-seq, which combines CRISPR-based perturbations with single-cell RNA sequencing, enables high-throughput measurement of perturbed gene expression signatures but lacks exon-level resolution, limiting its application for splicing factor activity analysis. Here, we show that shallow artificial neural networks can estimate splicing factor activity from gene expression signatures, bypassing the need for exon-level data. As a case study, we map the genetic interactions regulating splicing factors during carcinogenesis, using the shift in splicing program activity-where oncogenic-like splicing factors become more active than tumor suppressor-like factors-as a molecular reporter of a Perturb-seq screen. Our analysis reveals a cross-regulatory network among splicing factors, involving protein-protein and splicing-mediated interactions, with MYC and additional candidate pathways linking cancer driver mutations to splicing regulation. This regulation recapitulates splicing program dynamics during development. Altogether, we establish a versatile framework for studying splicing factor regulation and demonstrate its utility for uncovering disease mechanisms., This project was funded by the Ministerio de Ciencia, Innovación y Universidades and the Agencia Estatal de Investigación to L.S. (PID2021-122341NB-I00 project funded by MICIU/AEI/10.13039/501100011033 and ERDF, UE). Funding to pay the Open Access publication charges for this article was provided by PID2021-122341NB-I00
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Predicting interacting hotspots for nanobodies' binding using triplets of residues

  • Hamdani, Rahma
  • Cianferoni, Damiano
  • Reche, Raul
  • Delgado Blanco, Javier
  • Serrano Pubull, Luis, 1982-
Protein-protein interactions (PPI) are fundamental to cellular signaling, forming robust networks that govern critical biological processes such as immune response, cell growth, and signal transduction. Nanobody-based therapies have emerged as a key strategy for modulating PPIs, offering exceptional potential due to their high specificity, stability, and ability to access challenging epitopes on PPI interfaces inside cells. The rational design of nanobodies relies mainly on understanding and predicting their binding regions, particularly the residues that contribute the most to the binding energy (binding hotspots). Existing computational methods do not fully provide a scalable solution for hotspot identification in nanobody design, leaving a critical gap in the rational design of these therapeutics. Here, we present a scalable and structure-aware algorithm for hotspot prediction in nanobody design. The algorithm queries a curated database of triplets of interacting residues obtained from ~20,000 non-redundant PDB structures. We showed that these triplets contain structural and energetic information, being able to assess the stability effect of residue variations in protein structures, Pearson R = 0.63 (MSE = 1.58 kcal/mol). More important than effects on stability is the ability of the algorithm to predict binding hotspots of protein-protein generic complexes and more specifically in complexes containing nanobodies. HotspotPred reached an accuracy of 0.73 for hotspot residue identification in a protein interaction dataset of 1160 Alanine mutants and correctly identified in 63.4% of the cases we predicted at least 2 residues on the binding surface., This publication is part of the grant PRE2022-101389, funded by MICIU/AEI /10.13039/501100011033 and by the ESF+, and of the project PID2021-122341NB-I00, funded by MCIN/ AEI / 10.13039/501100011033 / FEDER, UE). This project has also received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 101020135).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

robustica: customizable robust independent component analysis

  • Anglada-Girotto, Miquel
  • Miravet Verde, Samuel, 1992-
  • Serrano Pubull, Luis, 1982-
  • Head, Sarah A.
Background: Independent Component Analysis (ICA) allows the dissection of omic datasets into modules that help to interpret global molecular signatures. The inherent randomness of this algorithm can be overcome by clustering many iterations of ICA together to obtain robust components. Existing algorithms for robust ICA are dependent on the choice of clustering method and on computing a potentially biased and large Pearson distance matrix. Results: We present robustica, a Python-based package to compute robust independent components with a fully customizable clustering algorithm and distance metric. Here, we exploited its customizability to revisit and optimize robust ICA systematically. Of the 6 popular clustering algorithms considered, DBSCAN performed the best at clustering independent components across ICA iterations. To enable using Euclidean distances, we created a subroutine that infers and corrects the components' signs across ICA iterations. Our subroutine increased the resolution, robustness, and computational efficiency of the algorithm. Finally, we show the applicability of robustica by dissecting over 500 tumor samples from low-grade glioma (LGG) patients, where we define two new gene expression modules with key modulators of tumor progression upon IDH1 and TP53 mutagenesis. Conclusion: robustica brings precise, efficient, and customizable robust ICA into the Python toolbox. Through its customizability, we explored how different clustering algorithms and distance metrics can further optimize robust ICA. Then, we showcased how robustica can be used to discover gene modules associated with combinations of features of biological interest. Taken together, given the broad applicability of ICA for omic data analysis, we envision robustica will facilitate the seamless computation and integration of robust independent components in large pipelines., This project was funded by grants from the Plan Estatal de Investigación Científica y Técnica y de Innovación to L.S. (PGC2018-101271-B-I00 and PID2021-122341NB-I00, http://www.ciencia.gob.es). We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. These funding bodies have not participated in the design of the study, collection, analysis, and interpretation of the data, nor in writing the manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

In silico RNA isoform screening to identify potential cancer driver exons with therapeutic applications

  • Anglada-Girotto, Miquel
  • Ciampi, Ludovica
  • Bonnal, Sophie
  • Head, Sarah A.
  • Miravet Verde, Samuel, 1992-
  • Serrano Pubull, Luis, 1982-
Alternative splicing is crucial for cancer progression and can be targeted pharmacologically, yet identifying driver exons genome-wide remains challenging. We propose identifying such exons by associating statistically gene-level cancer dependencies from knockdown viability screens with splicing profiles and gene expression. Our models predict the effects of splicing perturbations on cell proliferation from transcriptomic data, enabling in silico RNA screening and prioritizing targets for splicing-based therapies. We identified 1,073 exons impacting cell proliferation, many from genes not previously linked to cancer. Experimental validation confirms their influence on proliferation, especially in highly proliferative cancer cell lines. Integrating pharmacological screens with splicing dependencies highlights the potential driver exons affecting drug sensitivity. Our models also allow predicting treatment outcomes from tumor transcriptomes, suggesting applications in precision oncology. This study presents an approach to identifying cancer driver exon and their therapeutic potential, emphasizing alternative splicing as a cancer target., We thank Carolina Segura-Morales for the support in the experimental validations. We thank Javier Delgado and Damiano Cianferoni for their support in the structural analyzes. Also, we thank Juan Valcárcel, Manuel Irimia, Donate Weghorn, Xavier Hernandez-Alias, Marc Weber, and Reza Sodaei for the insightful discussions and feedback provided throughout the development of this project. We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA programme and to the EMBL partnership. We are grateful to the CRG Core Technologies Programme for their support and assistance in this work. The results shown here are in part based upon data generated by the TCGA Research Network (https://www.cancer.gov/tcga) and by Helsinki University (EGAD00001006456). Finally, we would like to thank the developer team behind VastDB as they created a resource that unifies and facilitates the splicing event-centric analysis of transcriptomes from the computational to the experimental sides. This project was funded by grants from the Plan Estatal de Investigación Científica y Técnica y de Innovación: PGC2018-101271-B-I00 and PID2021-122341NB-I00, (AEI/FEDER, UE) to L.S., and PID2021-122341NB-I00 project funded MICIU /AEI /10.13039/501100011033 / (FEDER, UE) to L.S.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Engineering Mycoplasma pneumoniae to bypass the association with Guillain-Barré syndrome

  • Broto, Alicia
  • Piñero-Lambea, Carlos
  • Segura-Morales, Carolina
  • Tio-Gillen, Anne P.
  • Unger, Wendy W. J.
  • Burgos, Raul
  • Mazzolini, Rocco
  • Miravet Verde, Samuel, 1992-
  • Jacobs, Bart C.
  • Casas, Josefina
  • Huizinga, Ruth
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
A non-pathogenic Mycoplasma pneumoniae-based chassis is leading the development of live biotherapeutic products (LBPs) for respiratory diseases. However, reports connecting Guillain-Barré syndrome (GBS) cases to prior M. pneumoniae infections represent a concern for exploiting such a chassis. Galactolipids, especially galactocerebroside (GalCer), are considered the most likely M. pneumoniae antigens triggering autoimmune responses associated with GBS development. In this work, we generated different strains lacking genes involved in galactolipids biosynthesis. Glycolipid profiling of the strains demonstrated that some mutants show a complete lack of galactolipids. Cross-reactivity assays with sera from GBS patients with prior M. pneumoniae infection showed that certain engineered strains exhibit reduced antibody recognition. However, correlation analyses of these results with the glycolipid profile of the engineered strains suggest that other factors different from GalCer contribute to sera recognition, including total ceramide levels, dihexosylceramide (DHCer), and diglycosyldiacylglycerol (DGDAG). Finally, we discuss the best candidate strains as potential GBS-free Mycoplasma chassis., This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme ERC LUNG-BIOREPAIR (101020135). We also acknowledge the support of the Spanish Ministry of Science and Innovation through the Plan Nacional PID2021-122341NB-I00 and the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), the Generalitat de Catalunya through the CERCA programme, the Center for Industrial Technology Development (CDTI) through the Neotec programme (SNEO 20211019) and to the EMBL partnership. C.P.-L. acknowledges the support of ‘Programa Torres Quevedo’ grant [PTQ2020-011048] funded by MCIN/AEI/10.13039/501100011033; European Union ‘NextGenerationEU/PRTR’. The proteomics analyses were performed in the CRG/UPF Proteomics Unit which is part of the Spanish National Infrastructure for Omics Technologies (ICTS OmicsTech). We thank T. Hoogenboezem and C. Gago da Graça (Department of Pediatrics, Erasmus MC–Sophia Children's Hospital, University Medical Centre, Rotterdam, The Netherlands) for excellent technical assistance.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Artificial intelligence and first-principle methods in protein redesign: A marriage of convenience?

  • Cianferoni, Damiano
  • Vizarraga, David
  • Fernández-Escamilla, Ana María
  • Fita, Ignacio
  • Hamdani, Rahma
  • Reche, Raúl
  • Delgado, Javier
  • Serrano, Luis
Since AlphaFold2's rise, many deep learning methods for protein design have emerged. Here, we validate widely used and recognized tools, compare them with first-principle methods, and explore their combinations, focusing on their effectiveness in protein redesign and potential for therapeutic repurposing. We address two challenges: evaluating tools and combinations ability to detect the effects of multiple concurrent mutations in protein variants, and leveraging large-scale datasets to compare modeling-free methods, namely force fields, which handle point mutations well with limited backbone rearrangement, and inverse folding tools, which excel at native sequence recovery but may struggle with non-natural proteins. Debuting TriCombine, a tool that identifies residue triangles in input structures, matches them to a structural database, and scores mutants based on substitution frequencies, we shortlisted candidates, modeled them with FoldX, and generated 16 SH3 mutants carrying up to 9 concurrent substitutions. The dataset was expanded to include 36 mutants and 11 crystal structures (7 newly solved), along with a parallel set of multiple non-concurrent mutants from three additional proteins. For broader validation, we analyzed 160,000 four-site GB1 mutants and 163,555 (single and double) variants across 179 natural and de novo domains. We show that combining AI-based modeling tools with force field scoring functions yields the most reliable results. Inverse folding tools perform very well but lose accuracy on less-represented proteins. First-principle force fields like FoldX remain the most accurate for point mutations. All methods perform worse when applied to unsolved de novo models, underscoring the need for hybrid strategies in robust protein design., Generalitat Valenciana, Grant/Award Number: AICO/2020/026; “la Caixa” Foundation, Grant/Award Number: LCF/BQ/ DI19/11730061; MCIN/ AEI / FEDER, UE, Grant/Award Number: PID2021-122341NBI00; Spanish National Plan for Scientific and Technical Research and Innovation, Grant/Award Number: BFU2015-63571-P; European Regional Development Fund; Centres de Recerca de Catalunya; Fundacion Carmen y Severo Ochoa, Grant/Award Number: CEX2020-001049-S, With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001049-S)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Using single-cell perturbation screens to decode the regulatory architecture of splicing factor programs

  • Anglada-Girotto, Miquel
  • Miravet Verde, Samuel, 1992-
  • Serrano Pubull, Luis, 1982-
Splicing factors shape the isoform pool of most transcribed genes, playing a critical role in cellular physiology. Their dysregulation is a hallmark of diseases like cancer, where aberrant splicing contributes to progression. While exon inclusion signatures accurately assess changes in splicing factor activity, systematically mapping disease-driver regulatory interactions at large scale remains challenging. Perturb-seq, which combines CRISPR-based perturbations with single-cell RNA sequencing, enables high-throughput measurement of perturbed gene expression signatures but lacks exon-level resolution, limiting its application for splicing factor activity analysis. Here, we show that shallow artificial neural networks can estimate splicing factor activity from gene expression signatures, bypassing the need for exon-level data. As a case study, we map the genetic interactions regulating splicing factors during carcinogenesis, using the shift in splicing program activity-where oncogenic-like splicing factors become more active than tumor suppressor-like factors-as a molecular reporter of a Perturb-seq screen. Our analysis reveals a cross-regulatory network among splicing factors, involving protein-protein and splicing-mediated interactions, with MYC and additional candidate pathways linking cancer driver mutations to splicing regulation. This regulation recapitulates splicing program dynamics during development. Altogether, we establish a versatile framework for studying splicing factor regulation and demonstrate its utility for uncovering disease mechanisms., This project was funded by the Ministerio de Ciencia, Innovación y Universidades and the Agencia Estatal de Investigación to L.S. (PID2021-122341NB-I00 project funded by MICIU/AEI/10.13039/501100011033 and ERDF, UE). Funding to pay the Open Access publication charges for this article was provided by PID2021-122341NB-I00
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Heterologous protein exposure and secretion optimization in Mycoplasma pneumoniae

  • Ana, Yamile
  • Gerngross, Daniel
  • Serrano Pubull, Luis, 1982-
The non-pathogenic Mycoplasma pneumoniae engineered chassis (Mycochassis) has demonstrated the ability to express therapeutic molecules in vitro and to be effective for treatment of lung infectious diseases in in vivo mouse models. However, the expression of heterologous molecules, whether secreted or exposed on the bacterial membrane has not been optimized to ensure sufficient secretion and/or exposure levels to exert a maximum in vivo biological effect. Here, we have improved the currently used secretion signal from MPN142 protein. We found that mutations at P1' position of the signal peptide cleavage site do not abrogate secretion but affect it. Increasing hydrophobicity and mutations at the C-terminal of the signal peptide increases secretion. We tested different lipoprotein signal peptides as possible N-terminal protein anchoring motifs on the Mpn cell surface. Unexpectedly we found that these peptides exhibit variable retention and secretion rates of the protein, with some sequences behaving as full secretion motifs. This raises the question of the biological role of the lipobox motif traditionally thought to anchor membrane proteins without a helical transmembrane domain. These results altogether represent a step forward in chassis optimization, offering different sequences for secretion or membrane retention, which could be used to improve Mycochassis as a delivery vector, and broadening its therapeutic possibilities., This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreements No 670216 and 101020135). We also acknowledge the support of the Spanish Ministry of Science, Innovation and Universities through the Plan Nacional PID2021-122341NB-I00 funded by MICIU/AEI/10.13039/501100011033/FEDER, UE.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

In silico RNA isoform screening to identify potential cancer driver exons with therapeutic applications

  • Anglada-Girotto, Miquel
  • Ciampi, Ludovica
  • Bonnal, Sophie
  • Head, Sarah A.
  • Miravet Verde, Samuel, 1992-
  • Serrano Pubull, Luis, 1982-
Alternative splicing is crucial for cancer progression and can be targeted pharmacologically, yet identifying driver exons genome-wide remains challenging. We propose identifying such exons by associating statistically gene-level cancer dependencies from knockdown viability screens with splicing profiles and gene expression. Our models predict the effects of splicing perturbations on cell proliferation from transcriptomic data, enabling in silico RNA screening and prioritizing targets for splicing-based therapies. We identified 1,073 exons impacting cell proliferation, many from genes not previously linked to cancer. Experimental validation confirms their influence on proliferation, especially in highly proliferative cancer cell lines. Integrating pharmacological screens with splicing dependencies highlights the potential driver exons affecting drug sensitivity. Our models also allow predicting treatment outcomes from tumor transcriptomes, suggesting applications in precision oncology. This study presents an approach to identifying cancer driver exon and their therapeutic potential, emphasizing alternative splicing as a cancer target., We thank Carolina Segura-Morales for the support in the experimental validations. We thank Javier Delgado and Damiano Cianferoni for their support in the structural analyzes. Also, we thank Juan Valcárcel, Manuel Irimia, Donate Weghorn, Xavier Hernandez-Alias, Marc Weber, and Reza Sodaei for the insightful discussions and feedback provided throughout the development of this project. We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA programme and to the EMBL partnership. We are grateful to the CRG Core Technologies Programme for their support and assistance in this work. The results shown here are in part based upon data generated by the TCGA Research Network (https://www.cancer.gov/tcga) and by Helsinki University (EGAD00001006456). Finally, we would like to thank the developer team behind VastDB as they created a resource that unifies and facilitates the splicing event-centric analysis of transcriptomes from the computational to the experimental sides. This project was funded by grants from the Plan Estatal de Investigación Científica y Técnica y de Innovación: PGC2018-101271-B-I00 and PID2021-122341NB-I00, (AEI/FEDER, UE) to L.S., and PID2021-122341NB-I00 project funded MICIU /AEI /10.13039/501100011033 / (FEDER, UE) to L.S.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Exon inclusion signatures enable accurate estimation of splicing factor activity

  • Anglada-Girotto, Miquel
  • Segura-Morales, Carolina
  • Moakley, Daniel F.
  • Zhang, Chaolin
  • Miravet Verde, Samuel, 1992-
  • Califano, Andrea
  • Serrano Sánchez, Antonio L.
Splicing factors control exon inclusion in messenger RNAs, shaping transcriptome and proteome diversity. Their catalytic activity is regulated by multiple layers, making single-omic measurements on their own fall short in identifying which splicing factors underlie a phenotype. Here, we posit that splicing factor activity, defined as a splicing factor's ability to modulate exon inclusion, can be estimated from changes in exon inclusion signatures. To test this hypothesis, we benchmark methods for constructing splicing factor-exon networks and estimating splicing factor activity. We find that combining RNA-seq perturbation-based networks with VIPER (Virtual Inference of Protein Activity by Enriched Regulon analysis) accurately captures splicing factor activity as modulated by multiple regulatory layers. This approach integrates splicing factor regulation into a single score derived solely from exon inclusion signatures, allowing functional interpretation of heterogeneous conditions. As a proof of concept, we identify recurrent cancer splicing programs, revealing associations with oncogenic- and tumor suppressor-like splicing factors missed by conventional methods. These programs correlate with patient survival and key cancer hallmarks: initiation, proliferation, and immune evasion. Altogether, we show splicing factor activity can be accurately estimated from exon inclusion changes, enabling comprehensive analyses of splicing regulation with minimal data requirements., We thank William C. Hahn, Annica Gad, Emma Lundberg, and Staffan Strömblad for kindly sharing the BJ fibroblasts and its derivatives with us. And, Attila Biçer and Matilde D'Angelo for their help in culturing BJ fibroblast cell lines. We would like to thank Luca Zanella, Lucas ZhongMing Hu, Alessandro Vasciaveo, Alec Wang for their support in the reimplementation of VIPER. We would like to thank Sophie Bonnal, Malgorzata Ewa Rogalska, Juan Valcárcel, Manuel Irimia, Yamile Ana, Javier Gonzalez-de-Miguel and Xavier Hernandez-Alias for the insightful discussions regarding the elucidation of splicing factor programs. Also, we would like to thank Hector C Keun, Clare Eckold and Anke Nijhuis for kindly sharing proteomics sample metadata and raw RNA sequencing data from cells treated with indisulam. We acknowledge support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA programme, and to the EMBL partnership. We are grateful to the CRG Core Technologies Programme for their support and assistance in this work. The proteomics analyses were performed in the CRG/UPF Proteomics Unit, which is part of the Spanish National Infrastructure for Omics Technologies (ICTS OmicsTech). The results shown here are in part based upon data generated by the TCGA Research Network (https://www.cancer.gov/tcga). This project was funded by grants from the Plan Estatal de Investigación Científica y Técnica y de Innovación to LS (PID2021-122341NB-I00 project funded MICIU / AEI / 10.13039 / 501100011033 / FEDER, UE). Further, the project was also supported by the NCI U54CA274506 (Center for Cancer Systems Therapeutics, CaST), the NCI Outstanding Investigator Award R35 CA197745, and the NIH Shared Instrumentation Grants S10 0D012351 and S10 OD021764 and S10 0D032433 all to AC. In addition, CZ was supported by grants from NIH (R01NS125018 and R35GM145279). And, MA-G was supported in part by a Boehringer Ingelheim Fonds travel grant.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

robustica: customizable robust independent component analysis

  • Anglada-Girotto, Miquel
  • Miravet Verde, Samuel, 1992-
  • Serrano Pubull, Luis, 1982-
  • Head, Sarah A.
Background: Independent Component Analysis (ICA) allows the dissection of omic datasets into modules that help to interpret global molecular signatures. The inherent randomness of this algorithm can be overcome by clustering many iterations of ICA together to obtain robust components. Existing algorithms for robust ICA are dependent on the choice of clustering method and on computing a potentially biased and large Pearson distance matrix. Results: We present robustica, a Python-based package to compute robust independent components with a fully customizable clustering algorithm and distance metric. Here, we exploited its customizability to revisit and optimize robust ICA systematically. Of the 6 popular clustering algorithms considered, DBSCAN performed the best at clustering independent components across ICA iterations. To enable using Euclidean distances, we created a subroutine that infers and corrects the components' signs across ICA iterations. Our subroutine increased the resolution, robustness, and computational efficiency of the algorithm. Finally, we show the applicability of robustica by dissecting over 500 tumor samples from low-grade glioma (LGG) patients, where we define two new gene expression modules with key modulators of tumor progression upon IDH1 and TP53 mutagenesis. Conclusion: robustica brings precise, efficient, and customizable robust ICA into the Python toolbox. Through its customizability, we explored how different clustering algorithms and distance metrics can further optimize robust ICA. Then, we showcased how robustica can be used to discover gene modules associated with combinations of features of biological interest. Taken together, given the broad applicability of ICA for omic data analysis, we envision robustica will facilitate the seamless computation and integration of robust independent components in large pipelines., This project was funded by grants from the Plan Estatal de Investigación Científica y Técnica y de Innovación to L.S. (PGC2018-101271-B-I00 and PID2021-122341NB-I00, http://www.ciencia.gob.es). We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. These funding bodies have not participated in the design of the study, collection, analysis, and interpretation of the data, nor in writing the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Predicting interacting hotspots for nanobodies' binding using triplets of residues

  • Hamdani, Rahma
  • Cianferoni, Damiano
  • Reche, Raul
  • Delgado Blanco, Javier
  • Serrano Pubull, Luis, 1982-
Protein-protein interactions (PPI) are fundamental to cellular signaling, forming robust networks that govern critical biological processes such as immune response, cell growth, and signal transduction. Nanobody-based therapies have emerged as a key strategy for modulating PPIs, offering exceptional potential due to their high specificity, stability, and ability to access challenging epitopes on PPI interfaces inside cells. The rational design of nanobodies relies mainly on understanding and predicting their binding regions, particularly the residues that contribute the most to the binding energy (binding hotspots). Existing computational methods do not fully provide a scalable solution for hotspot identification in nanobody design, leaving a critical gap in the rational design of these therapeutics. Here, we present a scalable and structure-aware algorithm for hotspot prediction in nanobody design. The algorithm queries a curated database of triplets of interacting residues obtained from ~20,000 non-redundant PDB structures. We showed that these triplets contain structural and energetic information, being able to assess the stability effect of residue variations in protein structures, Pearson R = 0.63 (MSE = 1.58 kcal/mol). More important than effects on stability is the ability of the algorithm to predict binding hotspots of protein-protein generic complexes and more specifically in complexes containing nanobodies. HotspotPred reached an accuracy of 0.73 for hotspot residue identification in a protein interaction dataset of 1160 Alanine mutants and correctly identified in 63.4% of the cases we predicted at least 2 residues on the binding surface., This publication is part of the grant PRE2022-101389, funded by MICIU/AEI /10.13039/501100011033 and by the ESF+, and of the project PID2021-122341NB-I00, funded by MCIN/ AEI / 10.13039/501100011033 / FEDER, UE). This project has also received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 101020135).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Engineering Mycoplasma pneumoniae to bypass the association with Guillain-Barré syndrome

  • Broto, Alicia
  • Piñero-Lambea, Carlos
  • Segura-Morales, Carolina
  • Tio-Gillen, Anne P.
  • Unger, Wendy W. J.
  • Burgos, Raul
  • Mazzolini, Rocco
  • Miravet Verde, Samuel, 1992-
  • Jacobs, Bart C.
  • Casas, Josefina
  • Huizinga, Ruth
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
A non-pathogenic Mycoplasma pneumoniae-based chassis is leading the development of live biotherapeutic products (LBPs) for respiratory diseases. However, reports connecting Guillain-Barré syndrome (GBS) cases to prior M. pneumoniae infections represent a concern for exploiting such a chassis. Galactolipids, especially galactocerebroside (GalCer), are considered the most likely M. pneumoniae antigens triggering autoimmune responses associated with GBS development. In this work, we generated different strains lacking genes involved in galactolipids biosynthesis. Glycolipid profiling of the strains demonstrated that some mutants show a complete lack of galactolipids. Cross-reactivity assays with sera from GBS patients with prior M. pneumoniae infection showed that certain engineered strains exhibit reduced antibody recognition. However, correlation analyses of these results with the glycolipid profile of the engineered strains suggest that other factors different from GalCer contribute to sera recognition, including total ceramide levels, dihexosylceramide (DHCer), and diglycosyldiacylglycerol (DGDAG). Finally, we discuss the best candidate strains as potential GBS-free Mycoplasma chassis., This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme ERC LUNG-BIOREPAIR (101020135). We also acknowledge the support of the Spanish Ministry of Science and Innovation through the Plan Nacional PID2021-122341NB-I00 and the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), the Generalitat de Catalunya through the CERCA programme, the Center for Industrial Technology Development (CDTI) through the Neotec programme (SNEO 20211019) and to the EMBL partnership. C.P.-L. acknowledges the support of ‘Programa Torres Quevedo’ grant [PTQ2020-011048] funded by MCIN/AEI/10.13039/501100011033; European Union ‘NextGenerationEU/PRTR’. The proteomics analyses were performed in the CRG/UPF Proteomics Unit which is part of the Spanish National Infrastructure for Omics Technologies (ICTS OmicsTech). We thank T. Hoogenboezem and C. Gago da Graça (Department of Pediatrics, Erasmus MC–Sophia Children's Hospital, University Medical Centre, Rotterdam, The Netherlands) for excellent technical assistance.